Evidence map›Paper›PMID 31764824›Full record

Trial reportMedicine2019

Diffusion-weighted image improves detectability of magnetic resonance cholangiopancreatography for pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasm.

Satoshi Kawakami, Mitsuharu Fukasawa, Tatsuya Shimizu, Shintaro Ichikawa, Tadashi Sato, Shinichi Takano, Makoto Kadokura, Hiroko Shindo, Ei Takahashi, Sumio Hirose and 10 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 1 institution in 1 country.

Satoshi KawakamiFirst Department of Internal Medicine.
Mitsuharu FukasawaFirst Department of Internal Medicine.
Tatsuya ShimizuDepartment of Radiology.
Shintaro IchikawaDepartment of Radiology.
Tadashi SatoFirst Department of Internal Medicine.
Shinichi TakanoFirst Department of Internal Medicine.
Makoto KadokuraFirst Department of Internal Medicine.
Hiroko ShindoFirst Department of Internal Medicine.
Ei TakahashiFirst Department of Internal Medicine.
Sumio HiroseFirst Department of Internal Medicine.
Yoshimitsu FukasawaFirst Department of Internal Medicine.
Hiroshi HayakawaFirst Department of Internal Medicine.
Yasuhiro NakayamaFirst Department of Internal Medicine.
Tatsuya YamaguchiFirst Department of Internal Medicine.
Taisuke InoueFirst Department of Internal Medicine.
Shinya MaekawaFirst Department of Internal Medicine.
Hiromichi KawaidaFirst Department of Surgery, Faculty of Medicine, University of Yamanashi; 1110 Shimokato, Chuo, Yamanashi, Japan.
Utaroh MotosugiDepartment of Radiology.
Hiroshi OnishiDepartment of Radiology.
Nobuyuki EnomotoFirst Department of Internal Medicine.
Health First · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study is aimed to clarify the utility of magnetic resonance cholangiopancreatography (MRCP) and the additional value of diffusion-weighted imaging (DWI) in diagnosing pancreatic ductal adenocarcinoma (PDAC) concomitant with intraductal papillary mucinous neoplasm (IPMN).This retrospective study involved 38 patients with PDAC concomitant with IPMN and 114 patients (control) who were randomly selected from 320 patients with IPMN without PDAC and were matched with cases for magnetic resonance imaging (MRI) strength (1.5 T/3.0 T). Two radiologists reviewed the 2 MR image sets with relevant clinical information blinded, first MRCP alone and then combined MRI set including DWI. Diagnostic capability and interobserver agreement were assessed by using receiver operating characteristics curve (Az) analysis and weighted κ statistics.Az values for the 2 observers were 0.834 and 0.821 for MRCP alone and 0.964 and 0.926 for the combined MRI (P < .001 and P < .001), respectively. The sensitivity of MRCP alone was 61% (23/38), with both observers failing to diagnose PDACs located at the end of tail or away from the pancreatic duct. Meanwhile, with combined MRI, sensitivity was significantly increased for both observers (61% to 92%, P = .002; 61% to 87%, P = .004). Moreover, the interobserver agreement was higher with combined MRI (κ = 0.85) than MRCP alone (κ = 0.59).MRCP and DWI might be a superior option with a higher diagnostic capability of PDAC concomitant with IPMN than MRCP alone, especially for tumors away from the pancreatic duct.

Indexed as

Diffusion Magnetic Resonance ImagingAdultAgedAged, 80 and overCarcinoma, Pancreatic DuctalCholangiopancreatography, Magnetic ResonanceFemaleHumansMaleMiddle AgedNeoplasms, Multiple PrimaryPancreatic Intraductal NeoplasmsPancreatic NeoplasmsRetrospective Studies

Identifiers

PMID31764824
PMCPMC6882617
OpenAlexW2989790616

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.